Cargando…
Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ). Recent studies reported consistently elevated expression levels of carbonic anhydrase CA2 in recurrent glioblastoma and temozolomide-resi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745118/ https://www.ncbi.nlm.nih.gov/pubmed/35008590 http://dx.doi.org/10.3390/ijms23010157 |
_version_ | 1784630268604186624 |
---|---|
author | Zhao, Kai Schäfer, Agnes Zhang, Zhuo Elsässer, Katharina Culmsee, Carsten Zhong, Li Pagenstecher, Axel Nimsky, Christopher Bartsch, Jörg W. |
author_facet | Zhao, Kai Schäfer, Agnes Zhang, Zhuo Elsässer, Katharina Culmsee, Carsten Zhong, Li Pagenstecher, Axel Nimsky, Christopher Bartsch, Jörg W. |
author_sort | Zhao, Kai |
collection | PubMed |
description | About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ). Recent studies reported consistently elevated expression levels of carbonic anhydrase CA2 in recurrent glioblastoma and temozolomide-resistant glioblastoma stem-like cells (GSCs). Here we show that CA2 is preferentially expressed in GSCs and upregulated by TMZ treatment. When expressed in GBM cell lines, CA2 exerts significant metabolic changes reflected by enhanced oxygen consumption and increased extracellular acidification causing higher rates of cell invasion. Notably, GBM cells expressing CA2 respond to combined treatment with TMZ and brinzolamide (BRZ), a non-toxic and potent CA2 inhibitor. Interestingly, brinzolamide was more effective than the pan-CA inhibitor Acetazolamide (ACZ) to sensitize naïve GSCs and TMZ-resistant GSCs to TMZ induced cell death. Mechanistically, we demonstrated that the combined treatment of GBM stem cells with TMZ and BRZ caused autophagy of GBM cell lines and GSCs, reflected by enhanced LC3 cleavage (LC3-II) and p62 reduction. Our findings illustrate the potential of CA2 as a chemo-sensitizing drug target in recurrent GBM and propose a combined treatment of TMZ with CA2 inhibitor to tackle GBM chemoresistance and recurrence. |
format | Online Article Text |
id | pubmed-8745118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87451182022-01-11 Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells Zhao, Kai Schäfer, Agnes Zhang, Zhuo Elsässer, Katharina Culmsee, Carsten Zhong, Li Pagenstecher, Axel Nimsky, Christopher Bartsch, Jörg W. Int J Mol Sci Article About 95% of Glioblastoma (GBM) patients experience tumor relapse as a consequence of resistance to the first-line standard chemotherapy using temozolomide (TMZ). Recent studies reported consistently elevated expression levels of carbonic anhydrase CA2 in recurrent glioblastoma and temozolomide-resistant glioblastoma stem-like cells (GSCs). Here we show that CA2 is preferentially expressed in GSCs and upregulated by TMZ treatment. When expressed in GBM cell lines, CA2 exerts significant metabolic changes reflected by enhanced oxygen consumption and increased extracellular acidification causing higher rates of cell invasion. Notably, GBM cells expressing CA2 respond to combined treatment with TMZ and brinzolamide (BRZ), a non-toxic and potent CA2 inhibitor. Interestingly, brinzolamide was more effective than the pan-CA inhibitor Acetazolamide (ACZ) to sensitize naïve GSCs and TMZ-resistant GSCs to TMZ induced cell death. Mechanistically, we demonstrated that the combined treatment of GBM stem cells with TMZ and BRZ caused autophagy of GBM cell lines and GSCs, reflected by enhanced LC3 cleavage (LC3-II) and p62 reduction. Our findings illustrate the potential of CA2 as a chemo-sensitizing drug target in recurrent GBM and propose a combined treatment of TMZ with CA2 inhibitor to tackle GBM chemoresistance and recurrence. MDPI 2021-12-23 /pmc/articles/PMC8745118/ /pubmed/35008590 http://dx.doi.org/10.3390/ijms23010157 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zhao, Kai Schäfer, Agnes Zhang, Zhuo Elsässer, Katharina Culmsee, Carsten Zhong, Li Pagenstecher, Axel Nimsky, Christopher Bartsch, Jörg W. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title_full | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title_fullStr | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title_full_unstemmed | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title_short | Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells |
title_sort | inhibition of carbonic anhydrase 2 overcomes temozolomide resistance in glioblastoma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745118/ https://www.ncbi.nlm.nih.gov/pubmed/35008590 http://dx.doi.org/10.3390/ijms23010157 |
work_keys_str_mv | AT zhaokai inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT schaferagnes inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT zhangzhuo inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT elsasserkatharina inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT culmseecarsten inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT zhongli inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT pagenstecheraxel inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT nimskychristopher inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells AT bartschjorgw inhibitionofcarbonicanhydrase2overcomestemozolomideresistanceinglioblastomacells |